{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:11Z","timestamp":1791209291719,"version":"4.1.0"},"reference-count":46,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA250972"],"award-info":[{"award-number":["P01CA250972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The absence of estrogen receptor, progesterone receptor, and HER2 expression limits the utility of targeted therapies in triple-negative breast cancer (TNBC). Chemotherapy is the standard of care for advanced TNBC but offers limited responses and an overall poor prognosis. We have developed several tumor-selective alkylphosphocholine analogs (NM600) for radiopharmaceutical therapy (RPT) of TNBC. Herein, we investigate the preclinical [225Ac]Ac-NM600 therapeutic efficacy and safety in two murine models of TNBC. NM600 was radiolabeled with 225Ac following previous methods. In vitro cytotoxicity studies were performed in metastatic (4T1) and non-metastatic (4T07) murine TNBC cells. Monte Carlo-based 225Ac dosimetry estimates enabled viability and clonogenic survival measurements in cells treated with 225Ac (0.03\u22121 Gy). Longitudinal ex vivo biodistribution studies were performed in BALB\/c mice bearing 4T1 or 4T07 tumor grafts injected with 9.25 kBq [225Ac]Ac-NM600 at 24, 72, 120, and 144 h post-injection (p.i.), and dosimetry estimation was performed using a MIRD formalism and a standard mouse model. Therapeutically, three groups of mice bearing 4T1 or 4T07 grafts (n \u29a55) received IV injections of vehicle, or 9.25 or 18.5 kBq [225Ac]Ac-NM600. Tumor volume and overall survival were monitored thrice weekly. Toxicity was evaluated in separate groups of BALB\/c mice (n = 3) at days 7, 30, 60, and 120 p.i. through complete blood count (CBC), serum chemistry, and histopathological analysis. [225Ac]Ac-NM600 was produced with high purity and serum stability. Clonogenic assays showed comparable dose-dependent 225Ac cytotoxicity in 4T1 and 4T07 cells, with an RBE of 5 compared to EBRT. Ex vivo biodistribution exhibited elevated and persistent tumor uptake, resulting in absorbed dose coefficients of 46 Gy\/\u03bcCi and 42 Gy\/\u03bcCi. Due to the hepatobiliary excretion of [225Ac]Ac-NM600, distribution in normal tissues was most prominent in the liver, with absorbed doses of 57 Gy\/\u03bcCi and 63 Gy\/\u03bcCi for mice bearing 4T1 and 4T07 tumors, respectively. Among other relevant tissues, blood and lungs were initially elevated but rapidly declined over time. [225Ac]Ac-NM600-treated mice exhibited significant tumor growth inhibition (p \u2264 0.015), with median survival of 21, 49, and 32 days, or 30, 77, and 64 days, for the vehicle, 9.25 kBq, and 18.5 kBq groups, in mice bearing 4T1 or 4T07 tumors, respectively. Only mild effects and no treatment-related mortality were observed in animals given [225Ac]Ac-NM600 9.25 or 18.5 kBq. Our findings underscore the potential of [225Ac]Ac-NM600 as a promising therapeutic agent for TNBC, warranting further assessments of efficacy and potential toxicities in additional TNBC animal models.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00252","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:01:45Z","timestamp":1790179305000},"page":"4831-4842","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of [225Ac]Ac-NM600 Therapeutic Potential for Localized and Metastatic Triple-Negative Breast Cancer"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1700-5436","authenticated-orcid":true,"given":"Yadira","family":"Medina Guevara","sequence":"first","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel Comas","family":"Rojas","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick Bio","family":"Idrissou","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila Lambert","family":"Lepesevich","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Wehner","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Lindsey","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2212Madison , , 600 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Carston","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8090-9930","authenticated-orcid":true,"given":"Nathan B.","family":"Clemons","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Mejia Montoya","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 396 Enzyme Institute 1710 University Avenue , , ,","place":["Madison, Wisconsin, United States, 53726"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Grudzinski","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2212Madison , , 600 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Bednarz","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P.","family":"Weichert","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2212Madison , , 600 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2179","authenticated-orcid":true,"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison , , 1111 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53705-2275"]},{"name":"University of Wisconsin\u2212Madison , , 600 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53792"]},{"name":"University of Wisconsin\u2212Madison , , 600 Highland Avenue , , ,","place":["Madison, Wisconsin, United States, 53792"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100509320382600_cit1","first-page":"12","article-title":"Diagnostic HER2-binding radiopharmaceutical, [68Ga]Ga-ABY-025, for routine clinical use in breast cancer patients","volume":"9","author":"Velikyan","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"2026100509320382600_cit2","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","article-title":"Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?","volume":"23","author":"Brenton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026100509320382600_cit3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2026100509320382600_cit4","doi-asserted-by":"publisher","first-page":"102855","DOI":"10.1016\/j.critrevonc.2019.102855","article-title":"Triple negative breast cancer: A thorough review of biomarkers","volume":"145","author":"da Silva","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026100509320382600_cit5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/BD-2010-0307","article-title":"Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer","volume":"32","author":"Chavez","year":"2011","journal-title":"Breast Dis."},{"key":"2026100509320382600_cit6","first-page":"95","article-title":"Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"2026100509320382600_cit7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.bcp.2007.07.041","article-title":"Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells","volume":"74","author":"Vink","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"2026100509320382600_cit8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1871520618666181012093056","article-title":"Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy","volume":"19","author":"Kaleag\u0306as\u0131og\u0306lu","year":"2019","journal-title":"Adv. Anticancer Agents Med. Chem."},{"key":"2026100509320382600_cit9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0005-2760(69)90217-3","article-title":"Occurrence and nature of O-alkyl and O-alk-I-enyl moieties of glycerol in lipids of Morris transplanted hepatomas and normal rat liver","volume":"176","author":"Snyder","year":"1969","journal-title":"Biochim. Biophys. Acta"},{"key":"2026100509320382600_cit10","first-page":"251","article-title":"Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues","volume":"29","author":"Snyder","year":"1969","journal-title":"Cancer Res."},{"key":"2026100509320382600_cit11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2967\/jnumed.119.236265","article-title":"177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer","volume":"61","author":"Hernandez","year":"2020","journal-title":"J. Nucl. Med."},{"key":"2026100509320382600_cit12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin\u2019s Lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun. Biol."},{"key":"2026100509320382600_cit13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/2326-6066.CIR-24-1191","article-title":"The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy","volume":"13","author":"Kerr","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"2026100509320382600_cit14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The Radiobiology of Radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semin. Radiat. Oncol."},{"key":"2026100509320382600_cit15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"2026100509320382600_cit16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discovery"},{"key":"2026100509320382600_cit17","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","article-title":"Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer","volume":"27","author":"Yam","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026100509320382600_cit18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and Response to Paclitaxel in Node-Positive Breast Cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2026100509320382600_cit19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2019","journal-title":"Lancet"},{"key":"2026100509320382600_cit20","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2026100509320382600_cit21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"2026100509320382600_cit22","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2026100509320382600_cit23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","article-title":"Neoadjuvant Talazoparib in Patients With Germline BRCA1\/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study","volume":"28","author":"Litton","year":"2023","journal-title":"Oncologist"},{"key":"2026100509320382600_cit24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1158\/1078-0432.CCR-24-2806","article-title":"Neoadjuvant Paclitaxel\/Olaparib in Comparison to Paclitaxel\/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study","volume":"31","author":"Fasching","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026100509320382600_cit25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026100509320382600_cit26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann. Oncol."},{"key":"2026100509320382600_cit27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2026100509320382600_cit28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026100509320382600_cit29","doi-asserted-by":"publisher","first-page":"S1148","DOI":"10.1016\/j.annonc.2020.08.2244","article-title":"LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer","volume":"31","author":"Emens","year":"2020","journal-title":"Ann. Oncol."},{"key":"2026100509320382600_cit30","doi-asserted-by":"publisher","first-page":"GS1-02","DOI":"10.1158\/1538-7445.SABCS21-GS1-02","article-title":"Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"82","author":"Cortes","year":"2022","journal-title":"Cancer Res."},{"key":"2026100509320382600_cit31","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2026100509320382600_cit32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"2026100509320382600_cit33","doi-asserted-by":"publisher","first-page":"22498","DOI":"10.1038\/s41598-022-27093-y","article-title":"Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer","volume":"12","author":"Izci","year":"2022","journal-title":"Sci. Rep."},{"issue":"23","key":"2026100509320382600_cit34","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","article-title":"Radioimmunotherapy of breast cancer metastases with \u03b1-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y","volume":"69","author":"Song","year":"2009","journal-title":"Cancer Res."},{"key":"2026100509320382600_cit35","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.2967\/jnumed.125.269601","article-title":"225Ac \u03b1-pretargeted radioimmunotherapy of human epidermal growth factor receptor 2\u2212expressing breast cancer","volume":"66","author":"Rinne","year":"2025","journal-title":"J. Nucl. Med."},{"key":"2026100509320382600_cit36","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1021\/jm050252g","article-title":"Synthesis and Structure\u2212Activity Relationship Effects on the Tumor Avidity of Radioiodinated Phospholipid Ether Analogues","volume":"49","author":"Pinchuk","year":"2006","journal-title":"J. Med. Chem."},{"key":"2026100509320382600_cit37","doi-asserted-by":"publisher","first-page":"240ra75","DOI":"10.1126\/scitranslmed.3007646","article-title":"Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy","volume":"6","author":"Weichert","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2026100509320382600_cit38","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1021\/acsomega.3c01547","article-title":"Evaluation of 89Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET","volume":"8","author":"Radaram","year":"2023","journal-title":"ACS Omega"},{"key":"2026100509320382600_cit39","doi-asserted-by":"publisher","first-page":"2022.09.26.509374","DOI":"10.1101\/2022.09.26.509374","article-title":"Profound immunomodulatory effects of 225 Ac-NM600 drive enhanced anti-tumor response in prostate cancer","author":"Ferreira","year":"2022","journal-title":"biorXiv"},{"key":"2026100509320382600_cit40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ijrobp.2025.09.072","article-title":"Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Murine Prostate Cancer Models","volume":"125","author":"Ferreira","year":"2026","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"2026100509320382600_cit41","doi-asserted-by":"publisher","first-page":"11435","DOI":"10.1002\/chem.202002999","article-title":"Synthesis and Evaluation of a Macrocyclic Actinium-225 Chelator, Quality Control and In Vivo Evaluation of 225 Ac-crown-\u03b1MSH Peptide","volume":"26","author":"Yang","year":"2020","journal-title":"Chem.\ue5f8Eur. J."},{"key":"2026100509320382600_cit42","doi-asserted-by":"publisher","first-page":"17823","DOI":"10.1021\/acs.jmedchem.5c01558","article-title":"Decadentate Acyclic Chelators for Lanthanum Radiopharmaceuticals","volume":"68","author":"Freire-Garci\u0301a","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026100509320382600_cit43","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2967\/jnumed.118.224808","article-title":"Preclinical characterization of 86\/90Y-NM600 in a variety of murine and human cancer tumor models","volume":"60","author":"Grudzinski","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026100509320382600_cit44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/cbr.2018.2451","article-title":"Development and validation of RAPID: A patient-specific Monte Carlo three-dimensional internal dosimetry platform","volume":"33","author":"Besemer","year":"2018","journal-title":"Cancer Biother. Radiopharm."},{"key":"2026100509320382600_cit45","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41467-026-68834-1","article-title":"Priming versus propagating: Distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice","volume":"17","author":"Kerr","year":"2026","journal-title":"Nat. Commun."},{"issue":"602","key":"2026100509320382600_cit46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00252","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4831\/68622915\/mp6c00252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4831\/68622915\/mp6c00252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:15Z","timestamp":1791208155000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4831\/5436732\/Preclinical-Evaluation-of-225Ac-Ac-NM600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00252","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}